Skip to contents
NHLBI Women's Health Initiative
Women's Health Initiative banner
 

WHI HOME

CONTACT

NHLBI POSTMENOPAUSAL HORMONE THERAPY

Estrogen-Alone Study

Estrogen-Plus-Progestin Study

WHI STUDY WEBSITE

Q & As for WHI STUDY PARTICIPANTS

WHI Background and Overview

WHI Update

Why WHI?

WHI Clinical Trial / Observational Study Locations

WHI Community Prevention Study

Additional Resources

   

The Estrogen-Plus-Progestin Study

The estrogen plus progestin trial was stopped in July 2002, after investigators found that the associated health risks of the combination hormone therapy outweighed the benefits. Participants were followed for an average of 5.6 years.

Selected Findings

Venous Thrombosis (October 2004)

Colorectal Cancer (March 2004)

Peripheral Arterial Disease Risk (February 2004)

Fracture Risk and Bone Mineral Density (October 2003)

Gynecologic Cancers and Diagnostic Procedures (October 2003)

Coronary Heart Disease Risk (August 2003)

Breast Cancer Risk (June 2003)

Dementia and Cognitive Function -- Women's Health Initiative Memory Study (May 2003)

Stroke Risk (May 2003)

Quality of life (March 2003)

Risks and Benefits of Combination Therapy (July 2002)

 
 
Department of Health and Human Services

 

National Institutes of Health

National Heart, Lung, and Blood Institute

Please send us your feedback, comments, and questions
by using the appropriate link on the page, Contact the NHLBI.

Note to users of screen readers and other assistive technologies: please report your problems here.

Link to DHHS Link to NIH Link to NHLBI Link to DHHS Link to WHI Home